Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
68.08 EUR | +0.11% | -0.07% | +100.15% |
Sales 2024 * | 123M 133M | Sales 2025 * | 325M 353M | Capitalization | 2.56B 2.78B |
---|---|---|---|---|---|
Net income 2024 * | -430M -467M | Net income 2025 * | -116M -126M | EV / Sales 2024 * | 21.6 x |
Net Debt 2024 * | 89.28M 96.88M | Net cash position 2025 * | 94.69M 103M | EV / Sales 2025 * | 7.58 x |
P/E ratio 2024 * |
-6.02
x | P/E ratio 2025 * |
-32.6
x | Employees | 464 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.13% |
Latest transcript on MorphoSys AG
1 day | +0.11% | ||
Current month | +2.87% | ||
1 month | +3.73% | ||
3 months | +4.51% | ||
6 months | +282.58% | ||
Current year | +100.29% |
Managers | Title | Age | Since |
---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 19-08-31 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 23-08-06 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 18-05-16 |
Director/Board Member | 67 | 18-05-16 | |
Marc Cluzel
CHM | Chairman | 69 | 12-05-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.44% | 125 M€ | -.--% | ||
0.80% | 17 M€ | -.--% | - | |
0.11% | 2 M€ | -.--% | ||
0.02% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-27 | 68.05 | +0.07% | 16 151 |
24-05-24 | 68 | -0.07% | 85,144 |
24-05-23 | 68.05 | -0.22% | 88,908 |
24-05-22 | 68.2 | -0.37% | 30,572 |
24-05-21 | 68.45 | +0.51% | 48,536 |
Delayed Quote Xetra, May 27, 2024 at 10:07 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+100.29% | 2.78B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.87% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- MOR Stock